To include your compound in the COVID-19 Resource Center, submit it here.

Prezista darunavir regulatory update

FDA approved an updated label for Johnson & Johnson's Prezista darunavir to include 192-week data

Read the full 152 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE